Xerthra™ kits

Xerthra™ kits – procedure packs for isolation and separation of platelet rich plasma (PRP) or injectible fibrine (iPRF) from patient’s peripheral blood.
Xerthra™ PRP kit provides  a fraction of autologus plasma with increased number of leukocytes which synthesize cytokines and higher amounts of platelets which release several types of growth factors for support tissue regeneration and healing processes.
Xerthra™ PRP kit guarantees uncomplicated, quick, and precise separation of highly concentrated (up to 9x) 1 to 3 ml of PRP with leukocytes from small amount of peripheral blood (15 ml with anticoagulant). Xerthra™ PRP kit is recommended for use in the inflammatory phase of the disease when regenerative action of growth factors as well as regulatory action of leukocytes are required.
Xerthra™ PRP PURE kit – procedure pack for isolation of platelet-rich plasma with reduced content of leukocytes (LP-PRP) from the patient’s peripheral blood. Autologous LP-PRP contains lower number of leukocytes and increased concentration of platelets rich in several growth factors which support healing of the injury over a shorter period of time with less side effects.Xerthra™ PRP PURE kit guarantees uncomplicated, precise and convenient isolation of concentrated LP-PRP (1 ml) with reduced number of erythrocytes and leukocytes obtained via double centrifugation of freshly drawn peripheral blood (15 ml with anticoagulant).LP-PRP is recommended for use in chronic, degenerative phase of the disease in which not inflammatory action of leukocytes but the regenerative action of growth factors contained in platelets is essential.

Xerthra™ iPRF kit – procedure pack for isolation of injectable platelet-rich fibrin (iPRF) from the patient’s peripheral blood. In the site of the injection autologous iPRF forms a fibrin network where leukocytes and platelets release cytokines and growth factors over a longer period of time.Xerthra™ iPRF kit guarantees isolation from 15 ml of blood of large amount of iPRF. Adjustable amounts of iPRF allows for the individual approach to the patient needs and the use of the required volume. The obtained preparation remains in the liquid form up to 20 minutes (in 37°C) after preparation, which significantly prolongs the time of application to the target site and guarantees effective penetration into hard-to-reach places. Procedure does not require chemical modification of the blood by addition of the anticoagulant.iPRF thanks to its unique ability for fibrin network creation is recommended to use in the injuries in which the prolongated regulatory as well as regenerative action of cytokines and growth factors is required.